Mylan N.V, Sandoz AG, and Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) are Dominating the EMEA Anorexiants Market in 2019

EMEA Anorexiants Market is expected to grow with a CAGR of 2.7% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report @ https://www.databridgemarketresearch.com/reports/emea-anorexiants-market

EMEA anorexiants market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in EMEA anorexiants market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In July 2019, Pfizer Inc. signed collaborative agreement with Mylan N.V. with an aim to enhance the generics drug portfolio. This collaboration helped the company to boost up its product portfolio of generic anorexiants drugs used for obesity treatment, which further helped the company to attain lucrative sales.

Mylan N.V. is the dominating player in EMEA anorexiants market. The other key players existing in the market VIVUS Inc, Recordati Rare Diseases (A Subsidiary of RECORDATI S.p.A.), Sun Pharmaceutical Industries Ltd., Pfizer Inc., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sandoz AG (A Business Division of Novartis AG), Mylan N.V., Bausch Health Companies Inc., Cipla Inc., Amphastar Pharmaceuticals, Inc. among others.

EMEA Anorexiants MarketMylan N.V.

Mylan N.V. is headquartered in Pennsylvania, U.S. The company focuses on manufacturing of high quality medicines involving generics, branded generics, over the counter and biosimilar drugs as per the new healthcare standards. The company has wide product portfolio involving biosimilars, generics, brand, over the counter, API in which generics is the market focused product.

For instance,

  • In November 2019, Mylan N.V. along with Pfizer Inc. established a new company and named it Viatris, which communicates the strength of the companies. This expansion helped the company to accelerate it business growth involving anorexiants drugs sales.

The company has wide presence across North America, Europe, South America, Asia-Pacific, Middle East and Africa. The company also has various subsidiary companies such Agila Australasia Pty Ltd (Australia), Alphapharm Pty. Ltd. (Australia), Meda Pharmaceuticals Pty Ltd (Australia), Mylan Australia Holding Pty Ltd (Australia), Mylan Health Pty. Ltd. (Australia), Arcana Arzneimittel GmbH (Austria) among others.

Sandoz AG (A Business Division of Novartis AG)

Sandoz AG (A Business Division of Novartis AG) is headquartered in New Jersey, U.S. The company is focused on manufacturing of generic and biosimilar medicines and is committed to play a leading role in driving access to various kinds of medicines worldwide. The company has various product categories which are non-Hiv antivirals, acne therapy, dermatologicals, hormones, psychotherapeutic drugs, antipruritics, antiinfectives, systemic, analeptics, muscle relaxants, anticoagulants, ophthalmic preparations, antinauseant NK1 MOD, anti-hyperlipidemic agent, antnfct, broad/med spec, vascular agents, miscellaneous, OTH, miscellaneous preps, bronchial therapy, diuretics, specific antagonists, psychotherapeutic drugs, antidepressants, analgesics, hormones, cort in comb, renin angiotensin antag, seizure disorders, movement disorders, inhib of glucan synthesis, antihistamines, systemic, anti-hyperlipidemic agent, musculoskeletal, anti-fungal agents, anti-neoplastic agents, oral contraceptives, menopause/vasomotor sympt, sex hormones, antiarthritics, cholesterol red, neurological disorders,oth, Gi antispasmodics, anti-fungal agents, antimalarials, tuberculosis therapy, anti-ulcerants, thyroid therapy, anesthetics, oxazolidinones, OTIC preparations, cardiac agents, anti-obesity preparations, potassium supplements, nutrients & supplements , cough/cold preps., Rx, enzymes, alzheimer-type dementia, benign prostate hypertrophy, miotics & glaucoma, natural medicine, immune system adjuncts, sedatives in which psychotherapeutic drugs, anti-obesity preparations are the market focused product categories.

  • In June 2019, Sandoz AG along with Novartis AG awarded with partnership award for their outstanding health care product distribution capacity. This award and recognition helped the company to maintain its continuous best role for various kinds of treatment involving obesity treatment among others.

The company has presence across Americas, Asia-Pacific, and Europe/Middle East/Africa. The company has various subsidiaries which are Sandoz Pty Ltd (Australia), Sandoz GmbH, Kundl (Austria), Sandoz NV, Vilvoorde (Belgium), Sandoz do Brasil Indústria Farmacêutica Ltda., Cambé, PR (Brazil), Sandoz s.r.o., Prague (Czech Republic) among others.

Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd)

Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd) is headquartered in New Jersey, U.S. The company is focused on development and production of affordable, high-quality generic drugs, innovative specialty pharmaceuticals and active pharmaceutical ingredients. The company has various product categories which are generic medicines, specialty medicines, biopharmaceuticals in these generic medicines and specialty medicines are the market focused category.

  • In February 2020, Teva Pharmaceutical Industries Ltd. obtained an economic benefit by saving billions via Teva’s generic medicines product portfolio. As the company is engaged in manufacturing of anorexiants generic medicines which are used for obesity treatment, this benefit helped the company to enhance its platform of anorexiants drugs. The company has presence in North America.